Trust Point Inc. Lowers Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Trust Point Inc. cut its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 26.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,786 shares of the biotechnology company's stock after selling 2,107 shares during the period. Trust Point Inc.'s holdings in Repligen were worth $833,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its position in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after acquiring an additional 130 shares in the last quarter. Blue Trust Inc. raised its stake in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 127 shares during the last quarter. Resources Management Corp CT ADV purchased a new position in shares of Repligen during the 3rd quarter worth approximately $37,000. Quarry LP grew its holdings in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 239 shares during the period. Finally, nVerses Capital LLC acquired a new stake in shares of Repligen in the 3rd quarter worth approximately $45,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Down 3.6 %

RGEN stock traded down $5.81 during midday trading on Friday, hitting $156.05. The company's stock had a trading volume of 409,305 shares, compared to its average volume of 563,368. The stock has a market capitalization of $8.74 billion, a P/E ratio of -421.75, a PEG ratio of 4.54 and a beta of 0.99. The company's fifty day moving average price is $155.37 and its 200 day moving average price is $148.69. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the prior year, the business earned $0.23 EPS. Repligen's quarterly revenue was up 9.7% on a year-over-year basis. As a group, equities research analysts predict that Repligen Co. will post 1.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating on the stock. HC Wainwright dropped their target price on Repligen from $240.00 to $180.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Friday, January 3rd. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $184.73.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.